Advanced Medical Isotope Corporation (OTC: ADMD) is engaged in the development of a brachytherapy device for the treatment of cancerous tumors. Brachytherapy uses radiation to destroy tumors by placing a radioactive isotope inside the treatment area. Currently, the company is pursuing FDA approval of its brachytherapy device, RadioGel, initially for the treatment of advanced basal and squamous skin cancers. Concurrently, the Company is pursuing development of veterinary applications for a range of cancers in collaboration with four leading university veterinary hospitals. Veterinary applications should have a faster path to revenue for ADMD, while providing data supporting the safety and therapeutic effectiveness of RadioGel. ADMD’s RadioGel requires no pre-market approval for pet therapy and the Company plans to generate near term revenue from veterinarian clinics and international licensing by 1Q18.

ADMD is in late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications. The Company plans to generate near-term revenue from veterinarian clinics and international licensing while pursuing FDA approval for multiple cancer indications. ADMD’s cancer treatment can disrupt the cancer treatment market, offering the potential upside of a drug with lower cost and shorter approval path of a device. Additionally, companies involved in brachytherapy treatment, such as Elekta AB ($3.5 billion) and Varian Medical Systems ($9.2 billion), provide an idea of valuation potential for ADMD, which represents significant upside from current levels.

 

  • Plans to generate near-term revenue from veterinarian clinics and international licensing by 1Q18
    • ADMD is in late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications

  • Company has the potential to disrupt the cancer treatment market with lower cost and shorter approval path of a cancer treatment device
    • Brachytherapy market is expected to reach $245 million by 2018
    • ADMD’s next-generation radiopharmaceutical therapeutic device uses hydrogel that is liquid at room temperature and solidifies at body temperate and locks in the particles

  • Company’s RadioGel requires no pre-market approval for pet therapy
    • Cancer is the leading cause of death for 32% of cats and 50% of dogs over age 10
    • Treating 10% of pet cancers at $5,000 average per treatment, generates $40 million annual revenue
    • Currently testing at leading university veterinary programs to demonstrate therapy across multiple indications

  • Strong leadership and word-class medical advisory board
    • More than 125 years combined experience; input from Mayo Clinic doctors


More Information | Company Website

 Disclosure

Investor Contact Info:

RedChip Companies Inc.
1017 Maitland Center Commons Blvd.
Maitland, FL 32751
(407) 644-4256
www.RedChip.com

 

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market